Q3 EPS Forecast for Tandem Diabetes Care Raised by Analyst

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Leerink Partnrs raised their Q3 2024 earnings per share (EPS) estimates for Tandem Diabetes Care in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.45). The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2024 earnings at ($1.71) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.81) EPS and FY2026 earnings at ($0.33) EPS.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, August 1st. The medical device company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $221.90 million for the quarter, compared to analysts’ expectations of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. Tandem Diabetes Care’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) EPS.

TNDM has been the subject of a number of other reports. UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Morgan Stanley restated an “equal weight” rating and set a $45.00 target price on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Wells Fargo & Company upped their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a research note on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price objective for the company. Finally, Robert W. Baird boosted their target price on Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and a consensus price target of $55.13.

Tandem Diabetes Care Trading Up 1.5 %

Shares of Tandem Diabetes Care stock opened at $35.34 on Friday. The business has a fifty day simple moving average of $41.98 and a 200-day simple moving average of $41.91. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $53.69. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -16.29 and a beta of 1.33. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. ORG Wealth Partners LLC acquired a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $30,000. ORG Partners LLC acquired a new stake in Tandem Diabetes Care in the second quarter valued at approximately $31,000. Headlands Technologies LLC bought a new stake in Tandem Diabetes Care in the first quarter worth approximately $35,000. MCF Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in shares of Tandem Diabetes Care during the 2nd quarter valued at $86,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.